Definitions used by the programme

For this data collection, this measure is defined as the total number of patients assessed for eligibility for tirzepatide (Mounjaro®) for the management of obesity through an approved OPIP delivery model during the reporting period. Eligibility should be assessed against the criteria agreed for each site’s approved approach, with prescribing remaining clinically appropriate and consistent with NICE technology appraisal TA1026. The SNOMED code(s) required to identify this activity are as follows:

For this data collection, this measure is defined as the total number of patients who started tirzepatide (Mounjaro®) for the management of obesity through an approved OPIP delivery model during the reporting period. Patients must meet the eligibility and assessment criteria agreed for the site’s approved approach, and prescribing must remain clinically appropriate and consistent with NICE technology appraisal TA1026. Only new treatment initiations should be counted; repeat prescriptions and dose titration should be excluded. The SNOMED code(s) required to identify this activity are as follows:

For this data collection, this measure is defined as the total number of patients referred to the national wraparound care service through an approved OPIP delivery model during the reporting period. Patients should meet the eligibility and assessment criteria agreed for the site’s approved approach, with referral and prescribing decisions remaining clinically appropriate and consistent with NICE technology appraisal TA1026.

*Patients referred to national and/or locally commissioned wraparound care should be reported in line with the support arrangements specified in the site’s approved OPIP delivery model.

For this data collection, this measure is defined as the total number of patients referred to locally commissioned wraparound care through an approved OPIP delivery model during the reporting period. Patients should meet the eligibility and assessment criteria agreed for the site’s approved approach, with referral and prescribing decisions remaining clinically appropriate and consistent with NICE technology appraisal TA1026.

The OPIP site must identify in its return that a locally commissioned arrangement is being used to provide wraparound care.

Patients referred to national and/or locally commissioned wraparound care should be reported in line with the support arrangements specified in the site’s approved OPIP delivery model.

For this data collection, this measure is defined as the total number of patients who met the eligibility and assessment criteria agreed for the site’s approved OPIP delivery model but declined tirzepatide (Mounjaro®) during the reporting period. The decision to offer treatment must remain clinically appropriate and consistent with NICE technology appraisal TA1026. Only patients who were offered tirzepatide and declined treatment should be included. The SNOMED code required to identify this activity is as follows:

For this data collection, this measure is defined as the total number of patients who stopped tirzepatide (Mounjaro®) for the management of obesity through an approved OPIP delivery model during the reporting period. Patients should previously have started treatment through the site’s approved approach, with treatment and discontinuation decisions remaining clinically appropriate and consistent with NICE technology appraisal TA1026. All treatment discontinuations should be included regardless of the reason for stopping. The SNOMED code required to identify this activity is as follows: